Eriko Tokunaga

9PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsClinical midwiferyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|May 19, 2026
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

|Feb 03, 2026
Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine.

Ayako Higuchi, Yumiko Koi, Tomoaki Eto

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Feb 02, 2025
The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer.

Eriko Tokunaga, Yumiko Koi, Wakako Tajiri

|Oct 08, 2024
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.

Eriko Tokunaga, Hiroji Iwata, Mitsuya Itoh

Pageof 2

Frequent Collaborators

2 joint publications

Xichun Hu

2 joint publications

Joohyuk Sohn

1 joint publications

Veronique Dieras

1 joint publications

Giuseppe Curigliano